Buprenorphine

證據等級: L5

預測適應症: 6 個

Buprenorphine: From Opioid Use Disorder / Pain Management to Acute Intermittent Porphyria

One-Sentence Summary

Buprenorphine is a partial μ-opioid receptor agonist with established use in opioid use disorder (OUD) treatment and moderate-to-severe pain management. The TxGNN model predicts it may be applicable to Acute Intermittent Porphyria (AIP), with 0 clinical trials and 1 publication currently available to support this direction — evidence remains extremely limited.

Quick Overview

Item	Content
Original Indication	Opioid use disorder; moderate-to-severe pain management
Predicted New Indication	Acute Intermittent Porphyria
TxGNN Prediction Score	99.41%
Evidence Level	L4
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known pharmacology, Buprenorphine is a partial agonist at the μ-opioid receptor and an antagonist at the κ-opioid receptor, giving it a distinctive profile among opioid analgesics — high-ceiling analgesia with a lower respiratory depression risk compared to full agonists.

Acute Intermittent Porphyria (AIP) is a rare metabolic disorder caused by a deficiency in the heme biosynthesis enzyme hydroxymethylbilane synthase (HMBS). During acute attacks, patients experience debilitating neuropathic abdominal pain along with autonomic instability and, in severe cases, neuropsychiatric symptoms. The critical clinical challenge is that many common analgesics and sedatives are porphyrinogenic (i.e., they can trigger or worsen attacks by inducing ALA synthase), making pain management particularly difficult.

The predicted link here is not disease-modifying but rather symptom-supportive: buprenorphine, as a non-porphyrinogenic opioid, is considered relatively safe for AIP pain management. The 1993 Japanese case report in the evidence pack describes anesthetic management in a patient with suspected AIP undergoing major surgery, which tangentially supports the notion that opioids (including agents in this class) can be used with caution in this population. However, this is a symptomatic analgesic application, not a targeted therapy addressing the underlying heme enzyme deficiency. The TxGNN model’s high prediction score likely reflects the graph-level mechanistic compatibility rather than a novel disease-modifying role.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
8301837	1993	Case Report	Masui (Japanese Journal of Anesthesiology)	Anesthetic management of a 40-year-old female with suspected AIP undergoing radical hysterectomy; describes the challenges of selecting porphyria-safe agents perioperatively. Buprenorphine is not directly evaluated but the case highlights the importance of opioid selection in AIP patients.

India Market Information

Buprenorphine currently has no registered products in the Indian market. No authorization records are available.

Safety Considerations

Drug Interactions: A total of 264 drug-drug interactions have been identified in the DDI database. Key interactions include:

Interacting Drug	Severity	Clinical Relevance
Alvimopan	Major	Opioid antagonist; concurrent use may precipitate withdrawal or loss of analgesic effect
Morphine	Major	Combined opioid use increases risk of CNS/respiratory depression
Bupropion	Major	May lower seizure threshold and alter opioid metabolism via CYP2D6 inhibition
Cisapride	Major	Risk of QT prolongation and potentially fatal arrhythmias
Dolasetron	Major	Additive QT prolongation risk
Famotidine	Moderate	May affect buprenorphine absorption/metabolism
Clarithromycin	Moderate	CYP3A4 inhibition may increase buprenorphine plasma levels
Dexamethasone	Moderate	CYP3A4 induction may reduce buprenorphine efficacy
Hyoscyamine / Atropine / Dicyclomine	Moderate	Additive anticholinergic effects
Loperamide	Moderate	Combined opioid effects on GI motility

Please refer to the package insert for full warnings and contraindications, as these data were not available in the current Evidence Pack.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for buprenorphine in acute intermittent porphyria is limited to a single indirect case report from 1993, with zero registered clinical trials. The proposed mechanism is symptomatic (analgesic support) rather than disease-modifying, and the drug is not currently approved or marketed in India, creating additional regulatory barriers.

To proceed, the following is needed:

Obtain the India/CDSCO package insert to assess key warnings, contraindications, and approved label language before any safety evaluation can proceed
Retrieve complete MOA data from DrugBank API (DB00921) to enable rigorous mechanistic analysis
Conduct a targeted literature review specifically examining buprenorphine (not opioids generally) as a safe analgesic in AIP, distinguishing it from porphyrinogenic agents
Explore whether any AIP pain management guidelines (e.g., European Porphyria Network / EPNET) list or exclude buprenorphine by name
If the intended application is purely symptomatic analgesia in AIP attacks, consider whether a full repurposing program is warranted versus a prescribing guidance / formulary inclusion initiative
Clarify the regulatory pathway for introducing buprenorphine to the Indian market, including controlled substance scheduling requirements

⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.